MEDIAN TECHNOLOGIES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.65 EUR | -1.35% |
|
-1.35% | -23.16% |
| May. 21 | Median Technologies Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company | CI |
| Apr. 29 | Median Technologies SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 23.9M 25.92M | Sales 2025 * | 44.18M 47.91M | Capitalization | 67.14M 72.82M |
|---|---|---|---|---|---|
| Net income 2024 * | -24M -26.03M | Net income 2025 * | -20M -21.69M | EV / Sales 2024 * | 3.61 x |
| Net Debt 2024 * | 19.25M 20.88M | Net Debt 2025 * | 39.23M 42.55M | EV / Sales 2025 * | 2.41 x |
| P/E ratio 2024 * |
-2.83
x | P/E ratio 2025 * |
-3.36
x | Employees | 256 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.99% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.35% | ||
| 1 week | -1.35% | ||
| 1 month | +40.66% | ||
| 3 months | -0.95% | ||
| 6 months | -6.41% | ||
| Current year | -23.16% |
1 week
3.41
3.89
1 month
2.603.89
Current year
2.335.06
1 year
2.336.77
3 years
2.3318.32
5 years
0.9318.32
10 years
0.9018.32
| Managers | Title | Age | Since |
|---|---|---|---|
Fredrik Brag
FOU | Founder | 62 | 01-12-31 |
| Director of Finance/CFO | - | 21-07-11 | |
Yan Liu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Oern Stuge
BRD | Director/Board Member | 70 | 20-06-24 |
Oran Muduroglu
CHM | Chairman | 62 | 08-03-25 |
Timothy Haines
BRD | Director/Board Member | 67 | 15-11-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 3.65 | -1.35% | 29,415 |
| 24-05-30 | 3.7 | +7.56% | 58,764 |
| 24-05-29 | 3.44 | -5.10% | 52,278 |
| 24-05-28 | 3.625 | +0.55% | 38,431 |
| 24-05-27 | 3.605 | -2.57% | 63,253 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT
More quotes
Median Technologies offers innovative imaging solutions and services to improve healthcare for all. The group uses the power of phenomic imaging to contribute to the emergence of new therapies and treatment strategies for patients. Its solutions, «iSee» for the image management in oncology trials and «eyonisTM» (formerly iBiopsy®), its phenomic imaging platform, combined with the expertise of its teams are an essential part to the discovery of new drugs and diagnostic tools to monitor diseases and evaluate the response of patients to their therapy. Median Technologies is helping biopharmaceutical companies and healthcare professionals quickly and accurately introduce new treatments to patients who need them, with a view to reducing overall costs of care.
Provision of services accounts for all net sales.
Net sales are distributed geographically as follows: China (41.6%), the United States and Canada (30.4%), Europe and other (28%).
Calendar
2024-10-16
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.65
EUR
Average target price
24.18
EUR
Spread / Average Target
+562.33%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.16% | 72.81M | |
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.48% | 64.59B | |
| +13.95% | 52.36B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.61B |
- Stock Market
- Equities
- ALMDT Stock
